Shocking New Insights Into the Epileptic Trait

Capturing the Epileptic Trait: Cortical Excitability Measures in Patients and Their Unaffected Siblings.

We used transcranial magnetic stimulation to investigate whether the cortical excitability changes observed amongst the different generalized and focal epilepsy syndromes are reflected in their asymptomatic siblings and if these changes depended on the clinical phenotype. We studied 157 patients with epilepsy (95 generalized and 62 focal) and their asymptomatic siblings (138 and 82, respectively). Motor threshold and paired pulse transcranial magnetic stimulation at short (2, 5, 10 and 15 ms) and long (100–300 ms) interstimulus intervals were measured. Results were compared to those of 12 control subjects and 20 of their siblings. There were no differences in cortical excitability between healthy control subjects and their siblings. Compared with control subjects, cortical excitability was higher in siblings of patients whether generalized (P<0.05; short and long interstimulus intervals) or focal (P<0.05; long interstimulus intervals). Compared with epilepsy, motor threshold was lower (P<0.05) in patients with juvenile myoclonic epilepsy compared with their siblings only early at onset in the drug naïve state. In all groups (generalized and focal) cortical excitability was lower in siblings only at the long interstimulus intervals (250 and 300; P<0.05). Cortical excitability is higher in asymptomatic siblings of patients with generalized and focal epilepsy in a similar manner. The disturbance seems to involve intracortical inhibitory circuits even in the siblings of patients with a structural abnormality (acquired epilepsy). This implies there are certain genetic factors that predispose to both generalized and focal epilepsies and a complex genetic/environmental interaction then determines the clinical phenotype.

Commentary

While epilepsy is a condition defined by chronic recurrent spontaneous seizures, a number of phenomena indicate that certain individuals who do not meet criteria for epilepsy nonetheless may have a tendency to have seizures, a "lower seizure threshold." This may include not only people with a single unprovoked seizure but also those with provoked ones, explaining why they have had a seizure while others in the same situation have not. There is also the issue of acquired focal epilepsy: Why do only a portion of patients with a given type of cerebral lesion develop seizures, and why do only some of these patients develop drug resistance? Finally, some first-degree relatives of individuals with epilepsy have interictal epileptiform discharges: in the current study, 8–13% of siblings of those with primary generalized epilepsy and 7% of siblings of refractory focal epilepsy patients. These situations reveal the existence of a subgroup of the "normal," nonepileptic population that has an increased risk of seizures. This could be explained by a genetically determined state, an "epileptic trait" manifested by spontaneous recurrent seizures (epilepsy) in only a portion of those affected. The addition of a CNS lesion, environmental circumstances, or co-occurrence of other genetic factors could lead to emergence of epilepsy in these predisposed individuals.

This current study used transcranial magnetic stimulation (TMS) to address this issue. TMS delivers a brief intense magnetic field to the scalp, inducing depolarizing electrical current in the underlying brain. This technique has been previously reviewed in Epilepsy Currents (1). One measure of excitability is the threshold for eliciting a muscle response from motor cortex activation. Excitability can also be measured with paired pulse stimulation, where a conditioning pulse is followed by a second test pulse; the ratio of the amplitude of the response to the test pulse to that of the conditioning pulse is measured as a function of the interstimulus interval (ISI). In this study, both hemispheres were stimulated. Short ISIs of 2–15 ms were performed with subthreshold conditioning stimuli followed by subthreshold pulses, typically producing facilitation at the longer intervals. Long ISIs used suprathreshold stimuli 100–300 ms apart, usually producing some inhibition of the second response. Abnormal cortical excitability was determined from shifts of these short and long ISI response curves for epilepsy patients and nonepileptic sibling groups compared to those of control subjects.

This approach has previously been validated as a useful tool for characterizing epilepsy. Not only does TMS demonstrate abnormal excitability in patients with different forms of epilepsy (1–9) but it also distinguishes between focal and generalized types; although both have increased excitability, this change is greater in the hemisphere ipsilateral to the side...
of seizure origination of focal epilepsy (2). TMS also reveals an additional increase in cortical excitability of epilepsy patients after sleep deprivation, particularly with idiopathic generalized epilepsy (3, 4). Introduction of antiepileptic drugs and achievement of seizure freedom results in near-normalization of cortical excitability, while drug resistance is associated with a broad increase in excitability (5, 6). Therefore, TMS responses are reliable markers of the type, severity, and natural history of epilepsy.

The current study found evidence of abnormal cortical excitability in the asymptomatic nonepileptic siblings of patients with a variety of generalized and focal epilepsy syndromes. Although this excitability was greater in siblings of those with generalized epilepsy, nevertheless, abnormal cortical excitability was present in siblings of those with all types of focal epilepsy, including seizure-free and drug-resistant subgroups. Many of these focal epilepsy patients had CNS lesions. Based on indirect evidence, the authors attributed the observed abnormalities of ISI response curves to defective GABAₐ and GABAᵦ mediated mechanisms. Therefore, these results demonstrate a familial abnormality of cortical excitability even in association with acquired epilepsies.

The TMS responses of the different subgroups of the 220 nonepileptic siblings were pooled and averaged. Although these subgroups, as a whole, had increased excitability, they were undoubtedly heterogeneous, containing individuals with normal cortical excitability as well as others with likely different forms of genetically determined defects affecting the balance between excitation and inhibition. These genotypes have not yet been defined.

There are many mutations known to lead to epilepsy. The most numerous are voltage- and ligand-gated channelopathies, and abnormalities of transmitter release (10). Many known epileptogenic mutations involve GABA transmission (10), congruent with the hypothesis that the abnormal cortical excitability detected with TMS is largely due to defective inhibition.

The current study supports the emerging concept that there are individuals who are susceptible to seizures, a larger group than that of people with epilepsy. Sometimes, this lower seizure threshold is unexpressed and silent; at other times, seizures or epilepsy emerges, depending on the severity of the seizure tendency, comorbidity, or environmental factors. TMS is a tool for detecting and characterizing the invisible population at risk for seizures. Thus, elucidating the different mechanisms underlying this phenotype of the "epileptic trait" may be an important step in unraveling the genetics of epilepsy.

by John W. Miller, MD, PhD

References

Instructions
The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.
   Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.

2. The work under consideration for publication.
   This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.
   This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (DGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

   Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

   For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Other relationships
   Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.
Section #1 Identifying Information

1. Today’s Date: 7/25/12

2. First Name John  Last Name Miller  Degree MD, PhD

3. Are you the Main Assigned Author?  ☒ Yes  ☐ No

   If no, enter your name as co-author:

4. Manuscript/Article Title: Shocking New Insights Into the Epileptic Trait

5. Journal Issue you are submitting for: 13.5

Section #2 The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Grant</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consulting fee or honorarium</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Support for travel to meetings for the study or other purposes</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Payment for writing or reviewing the manuscript</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Provision of writing assistance, medicines, equipment, or administrative support.</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Other</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.
** Use this section to provide any needed explanation.
Section #3 Relevant financial activities outside the submitted work.
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type of relationship (in alphabetical order)</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Board membership</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consultancy</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Employment</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Expert testimony</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Grants/grants pending</td>
<td>☐</td>
<td>Yes</td>
<td>NIH, CDC, Sunovian, UCB, Esai, Pfizer</td>
<td>ROSE study, Project Uplift, Investigational antiepileptic medication trials</td>
<td></td>
</tr>
<tr>
<td>6. Payment for lectures including service on speakers bureaus</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Payment for manuscript preparation</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Patents (planned, pending or issued)</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Royalties</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Payment for development of educational presentations</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Stock/stock options</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Travel/accommodations/meeting expenses unrelated to activities listed.**</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Other (err on the side of full disclosure)</td>
<td>☐</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section #4 Other relationships
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☒ No other relationships/conditions/circumstances that present a potential conflict of interest.
☐ Yes, the following relationships/conditions/circumstances are present:

John W. Miller
Thank you for your assistance.

Epilepsy Currents Editorial Board